Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

August 4, 2020
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Aug. 04, 2020 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon’s Chief Executive Officer, will participate in the following virtual investor conferences: William Blair Biotech Focus Conference 2020 | Panel 4: New Therapies Impacting the Epilepsy Treatment Landscape on Thursday, August … Continue reading Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

August 4, 2020
Aurinia Pharmaceuticals Inc.

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020 at 11:00 a.m. EDT. In order to participate in the audio webcast, … Continue reading Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

iCo Therapeutics Inc. Announces Publication of Oral Amphotericin B (iCo 019) Phase 1 Safety Study Results in Prestigious Infectious Diseases Journal

July 31, 2020
iCo Therapeutics Inc.

Vancouver, British Columbia–(Newsfile Corp. – July 30, 2020) – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or “the Company”) and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today the publication of results of their Oral Amphotericin B (iCo 019) Phase 1a Study in one of the leading infectious diseases journals, Antimicrobial Agents and … Continue reading iCo Therapeutics Inc. Announces Publication of Oral Amphotericin B (iCo 019) Phase 1 Safety Study Results in Prestigious Infectious Diseases Journal

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update

July 30, 2020
XENON PHARMACEUTICALS INC.

BURNABY, British Columbia, July 30, 2020 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it will report its second quarter 2020 financial and operating results after the close of U.S. financial markets on Thursday, August 6, 2020. Xenon management will host a conference call and live audio webcast … Continue reading Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update

Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020

July 30, 2020
Aurinia Pharmaceuticals Inc.

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the markets close. Aurinia’s executive team will host a conference call to discuss the Company’s financial results and to provide a general business … Continue reading Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020

Health Research Foundation awards Research Chair in Pandemic Preparedness Research to UBC professor

July 29, 2020
Innovative Medicines Canada (IMC)

Ottawa, July 29, 2020 – The Health Research Foundation (HRF) of Innovative Medicines Canada (IMC) is pleased to announce that Dr. Srinivas Murthy, clinical associate professor in the department of pediatrics at the University of British Columbia and critical care specialist and investigator at the BC Children’s Hospital, has been awarded the Health Research Foundation … Continue reading Health Research Foundation awards Research Chair in Pandemic Preparedness Research to UBC professor

Baxter and Ayogo Announce Partnership for Unique Digital Health Solutions for Home Dialysis

July 29, 2020
Ayogo Health Inc.

Companies forge exclusive partnership to advance digital health solutions that educate and empower patients with kidney failure The companies’ first mobile app, CKD&Me, launched in the United States; now preparing for global expansion Collaboration expected to also bring new patient mobile capabilities to Baxter’s Sharesource telehealth platform to support patient engagement and therapy management DEERFIELD, … Continue reading Baxter and Ayogo Announce Partnership for Unique Digital Health Solutions for Home Dialysis

HEALTH CANADA GRANTS MARKETING AUTHORIZATION WITH CONDITIONS (NOC/c) FOR GILEAD’S VEKLURY® (REMDESIVIR) FOR THE TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19)

July 29, 2020
Gilead Sciences, Inc.

—Veklury is the First Approved Treatment Option for COVID-19 in Canada — Mississauga, ON, July 28, 2020 – Gilead Sciences Canada, Inc. today announced that Health Canada has issued a marketing authorization with conditions (Notice of Compliance with Conditions, or NOC/c) for Veklury® (remdesivir). Under this conditional authorization, Veklury is indicated for the treatment of … Continue reading HEALTH CANADA GRANTS MARKETING AUTHORIZATION WITH CONDITIONS (NOC/c) FOR GILEAD’S VEKLURY® (REMDESIVIR) FOR THE TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19)

Arbutus to Report Second Quarter 2020 Financial Results

July 29, 2020
Arbutus Biopharma Corp.

WARMINSTER, Pa., July 29, 2020 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its second quarter financial results, conference call and … Continue reading Arbutus to Report Second Quarter 2020 Financial Results

Aurinia Closes US$200 Million Public Offering of Common Shares

July 27, 2020
Aurinia Pharmaceuticals Inc.

July 27, 2020, VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the closing of its previously announced underwritten public offering of 13,333,334 common shares (the “Offering”). The shares were sold at a public offering price of … Continue reading Aurinia Closes US$200 Million Public Offering of Common Shares